Narcolepsy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F Segmented by Type (Type 1, Type 2, Others), By Diagnosis (Polysomnogram, Multiple Sleep Latency Test, Others), By Treatment (Stimulants, Antidepressants, Sodium Oxybate, Others), By End User (Hospitals, Clinics, Retail Pharmacies, Others), By Region and Competition
The global narcolepsy market is anticipated to register an impressive growth rate during the forecast period. This can be ascribed to the rising number and size of investments in the healthcare sector for the treatment of sleep disorders across the region. Additionally, the growing prevalence of neurological disorders such as sleep apnea and insomnia due to stressful lifestyles is expected to drive the growth of the market over the years. Similarly, the major players are investing in the development of narcolepsy drugs at low cost, which is expected to further drive the growth of the market over the forecast period, according to Clinical trials. Gov,131 studies have been found for narcolepsy drugs. Among them, narcolepsy cataplexy-type drugs can be taken by both males and females between 18-55 years of age. Moreover, significant improvements in the diagnostic technologies for narcolepsy and pharmaceutical companies are developing variants with long-term benefits and reduced side which are further expected to increase the demand for narcolepsy, thereby fuelling the market growth through 2028. Furthermore, an increasing number of major players in the market focusing on developing new drugs and therapies for the benefit of users is further expected to increase the demand for narcolepsy, thereby supporting the market growth. According to CDC, in 2020, 34.8 % of people were affected with narcolepsy or sleep disorder among the U.S population.
Growing Prevalence of Narcolepsy
The growing severity of the disease and the growing number of people affected by narcolepsy due to stressful lifestyles, an inherited genetic fault, hormonal changes that take place during puberty or menopause, and a sudden change in sleep patterns are the main factors driving the growth of the market during the forecast period. Moreover, narcolepsy medications can also be used to treat sleep apnea, insomnia, and restless legs syndrome, which will further drive the growth of the market. The major drivers of the narcolepsy market growth throughout the forecast period are rising narcolepsy prevalence and a growing obese population. In addition, because it has fewer adverse effects than other stimulants, the use of modafinil to treat patients is adding to its market expansion. So, proper treatment can aid in the prevention of such ailments, which is expected to drive the global narcolepsy market. It's estimated that 1 to 4% of children suffer from sleep apnea, many of them being between 2 and 8 years old.
Growing Initiatives by Government Organizations
Growing awareness about narcolepsy treatment among the population is expected to create significant growth during the forecast period. Moreover, the use of modafinil to treat patients because it has fewer side effects, and it can help to prevent such disorders, thereby driving the narcolepsy market during the forecast period. Government organizations from different countries, such as India and South Africa, have taken initiatives for campaigns to educate people and health workers about the narcolepsy drug’s advantages and narcolepsy treatment in developing as well as rural areas, which is expected to boost market growth during the forecast period. According to the National Institute of Neurological Disorders and Stroke fact sheet updated in November 2021, narcolepsy affects anywhere between 135,000 and 200,000 people in the United States. The rise in donations for the development of narcolepsy treatments in the United States is further anticipated to drive the growth of the market over the years. Moreover, the rapid adoption of a new therapy for the treatment of narcolepsy drugs is anticipated to drive market growth over the forecast period. Furthermore, Project Sleep, a non-profit organization based in the United States, launched a program called 'Rising Voices of Narcolepsy' to educate people about narcolepsy to share their stories through writing and verbally addressing local communities to raise awareness and reduce social stigma among others suffering from the disease.
Market Segmentation
The global narcolepsy market can be segmented on the basis of type, diagnosis, treatment, end user, and by region. Based on the type, the market can be segmented into Type 1, Type 2, and Others. Based on the diagnosis, the market can be further divided into polysomnograms, multiple sleep latency tests, and others. On the basis of the treatment, the market can be further split into stimulants, antidepressants, sodium oxybate, and others. Based on end users, the market can be split into hospitals, clinics, retail pharmacies, and others. On the basis of region, North America dominated the market among Asia Pacific, Europe, Middle East & Africa, and South America. Among the different countries, the United States dominated the global narcolepsy market on account of the increasing incidence of sleep disorders in the country.
Recent Development
Jazz Pharmaceuticals Plc., BIOPROJET., Arena Pharmaceuticals, Inc., Graymark Healthcare, Inc., Mylan N.V., Teva Pharmaceutical Industries Ltd., Novartis AG., Shire., Shionogi Inc., Ligand Pharmaceuticals, Inc are some of the leading players operating in the Global Narcolepsy Market.
Report Scope:
In this report, the global narcolepsy market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:
Company Profiles: Detailed analysis of the major companies present in the Global Narcolepsy Market.
Available Customizations:
With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:
Company Information
Growing Prevalence of Narcolepsy
The growing severity of the disease and the growing number of people affected by narcolepsy due to stressful lifestyles, an inherited genetic fault, hormonal changes that take place during puberty or menopause, and a sudden change in sleep patterns are the main factors driving the growth of the market during the forecast period. Moreover, narcolepsy medications can also be used to treat sleep apnea, insomnia, and restless legs syndrome, which will further drive the growth of the market. The major drivers of the narcolepsy market growth throughout the forecast period are rising narcolepsy prevalence and a growing obese population. In addition, because it has fewer adverse effects than other stimulants, the use of modafinil to treat patients is adding to its market expansion. So, proper treatment can aid in the prevention of such ailments, which is expected to drive the global narcolepsy market. It's estimated that 1 to 4% of children suffer from sleep apnea, many of them being between 2 and 8 years old.
Growing Initiatives by Government Organizations
Growing awareness about narcolepsy treatment among the population is expected to create significant growth during the forecast period. Moreover, the use of modafinil to treat patients because it has fewer side effects, and it can help to prevent such disorders, thereby driving the narcolepsy market during the forecast period. Government organizations from different countries, such as India and South Africa, have taken initiatives for campaigns to educate people and health workers about the narcolepsy drug’s advantages and narcolepsy treatment in developing as well as rural areas, which is expected to boost market growth during the forecast period. According to the National Institute of Neurological Disorders and Stroke fact sheet updated in November 2021, narcolepsy affects anywhere between 135,000 and 200,000 people in the United States. The rise in donations for the development of narcolepsy treatments in the United States is further anticipated to drive the growth of the market over the years. Moreover, the rapid adoption of a new therapy for the treatment of narcolepsy drugs is anticipated to drive market growth over the forecast period. Furthermore, Project Sleep, a non-profit organization based in the United States, launched a program called 'Rising Voices of Narcolepsy' to educate people about narcolepsy to share their stories through writing and verbally addressing local communities to raise awareness and reduce social stigma among others suffering from the disease.
Market Segmentation
The global narcolepsy market can be segmented on the basis of type, diagnosis, treatment, end user, and by region. Based on the type, the market can be segmented into Type 1, Type 2, and Others. Based on the diagnosis, the market can be further divided into polysomnograms, multiple sleep latency tests, and others. On the basis of the treatment, the market can be further split into stimulants, antidepressants, sodium oxybate, and others. Based on end users, the market can be split into hospitals, clinics, retail pharmacies, and others. On the basis of region, North America dominated the market among Asia Pacific, Europe, Middle East & Africa, and South America. Among the different countries, the United States dominated the global narcolepsy market on account of the increasing incidence of sleep disorders in the country.
Recent Development
- In December 2021, Ligand Pharmaceuticals, Inc. announced the expansion of its existing collaboration and license agreement between its subsidiary, Icagen, and GSK. This expansion will leverage Icagen’s ion-channel-based discovery technology and unique expertise in small molecule therapeutics targeting transmembrane proteins. This new agreement builds upon the initial December 2020 agreement to identify and develop inhibitors of a specific genetically-validated molecular target relevant to neurological diseases.
- In January 2020, Adare Pharmaceuticals, Inc. and NLS Pharmaceutics Ltd. collaborated to develop mazindol CR product candidates for the treatment of narcolepsy and Attention Deficit Hyperactivity Disorder (ADHD).
Jazz Pharmaceuticals Plc., BIOPROJET., Arena Pharmaceuticals, Inc., Graymark Healthcare, Inc., Mylan N.V., Teva Pharmaceutical Industries Ltd., Novartis AG., Shire., Shionogi Inc., Ligand Pharmaceuticals, Inc are some of the leading players operating in the Global Narcolepsy Market.
Report Scope:
In this report, the global narcolepsy market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:
- Narcolepsy Market, By Type:
- Type 1
- Type 2
- Others
- Narcolepsy Market, By Diagnosis:
- Polysomnogram
- Multiple Sleep Latency Test
- Others
- Narcolepsy Market, By Treatment:
- Stimulants
- Antidepressants
- Sodium Oxybate
- Others
- Narcolepsy Market, By Route of End User:
- Hospitals
- Clinics
- Retail Pharmacies
- Others
- Narcolepsy Market, By Region:
- North America
- United States
- Canada
- Mexico
- Europe
- France
- Germany
- United Kingdom
- Italy
- Spain
- Asia Pacific
- China
- India
- Japan
- South Korea
- Australia
- South America
- Brazil
- Argentina
- Colombia
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
Company Profiles: Detailed analysis of the major companies present in the Global Narcolepsy Market.
Available Customizations:
With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to five).
1. PRODUCT OVERVIEW
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. VOICE OF CUSTOMER
5. CLINICAL TRIAL ANALYSIS
5.1. Ongoing Clinical Trials
5.2. Completed Clinical Trials
5.3. Terminated Clinical Trials
5.4. Breakdown of Pipeline, By Development Phase
5.5. Breakdown of Pipeline, By Status
5.6. Breakdown of Pipeline, By Study Type
5.7. Breakdown of Pipeline, By Region
5.8. Clinical Trials Heat Map
6. GLOBAL NARCOLEPSY MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Type (Type 1, Type 2, Others)
6.2.2. By Diagnosis (Polysomnogram, Multiple Sleep Latency Test, Others)
6.2.3. By Treatment (Stimulants, Antidepressants, Sodium Oxybate, Others)
6.2.4. By End User (Hospitals, Clinics, Retail Pharmacies, Others)
6.2.5. By Company (2022)
6.3. Product Map
6.3.1 By Type
6.3.2 By Diagnosis
6.3.3 By Treatment
6.3.4 By End User
7. NORTH AMERICA NARCOLEPSY MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Type (Type 1, Type 2, Others)
7.2.2. By Diagnosis (Polysomnogram, Multiple Sleep Latency Test, Others)
7.2.3. By Treatment (Stimulants, Antidepressants, Sodium Oxybate, Others)
7.2.4. By End User (Hospitals, Clinics, Retail Pharmacies, Others)
7.2.5. By Country
7.3. North America: Country Analysis
7.3.1. United States Narcolepsy Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Type
7.3.1.2.2. By Diagnosis
7.3.1.2.3. By Treatment
7.3.1.2.4. By End User
7.3.2. Canada Narcolepsy Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Type
7.3.2.2.2. By Diagnosis
7.3.2.2.3. By Treatment
7.3.2.2.4. By End User
7.3.3. Mexico Narcolepsy Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Type
7.3.3.2.2. By Diagnosis
7.3.3.2.3. By Treatment
7.3.3.2.4. By End User
8. EUROPE NARCOLEPSY MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Type (Type 1, Type 2, Others)
8.2.2. By Diagnosis (Polysomnogram, Multiple Sleep Latency Test, Others)
8.2.3. By Treatment (Stimulants, Antidepressants, Sodium Oxybate, Others)
8.2.4. By End User (Hospitals, Clinics, Retail Pharmacies, Others)
8.2.5. By Country
8.3. Europe: Country Analysis
8.3.1. France Narcolepsy Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Type
8.3.1.2.2. By Diagnosis
8.3.1.2.3. By Treatment
8.3.1.2.4. By End User
8.3.2. Germany Narcolepsy Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Type
8.3.2.2.2. By Diagnosis
8.3.2.2.3. By Treatment
8.3.2.2.4. By End User
8.3.3. United Kingdom Narcolepsy Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Type
8.3.3.2.2. By Diagnosis
8.3.3.2.3. By Treatment
8.3.3.2.4. By End User
8.3.4. Italy Narcolepsy Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Type
8.3.4.2.2. By Diagnosis
8.3.4.2.3. By Treatment
8.3.4.2.4. By End User
8.3.5. Spain Narcolepsy Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Type
8.3.5.2.2. By Diagnosis
8.3.5.2.3. By Treatment
8.3.5.2.4. By End User
9. ASIA-PACIFIC NARCOLEPSY MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Type (Type 1, Type 2, Others)
9.2.2. By Diagnosis (Polysomnogram, Multiple Sleep Latency Test, Others)
9.2.3. By Treatment (Stimulants, Antidepressants, Sodium Oxybate, Others)
9.2.4. By End User (Hospitals, Clinics, Retail Pharmacies, Others)
9.2.5. By Country
9.3. Asia-Pacific: Country Analysis
9.3.1. China Narcolepsy Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Type
9.3.1.2.2. By Diagnosis
9.3.1.2.3. By Treatment
9.3.1.2.4. By End User
9.3.2. India Narcolepsy Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Type
9.3.2.2.2. By Diagnosis
9.3.2.2.3. By Treatment
9.3.2.2.4. By End User
9.3.3. Japan Narcolepsy Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Type
9.3.3.2.2. By Diagnosis
9.3.3.2.3. By Treatment
9.3.3.2.4. By End User
9.3.4. South Korea Narcolepsy Market Outlook
9.3.4.1. Market Size & Forecast
9.3.4.1.1. By Value
9.3.4.2. Market Share & Forecast
9.3.4.2.1. By Type
9.3.4.2.2. By Diagnosis
9.3.4.2.3. By Treatment
9.3.4.2.4. By End User
9.3.5. Australia Narcolepsy Market Outlook
9.3.5.1. Market Size & Forecast
9.3.5.1.1. By Value
9.3.5.2. Market Share & Forecast
9.3.5.2.1. By Type
9.3.5.2.2. By Diagnosis
9.3.5.2.3. By Treatment
9.3.5.2.4. By End User
10. SOUTH AMERICA NARCOLEPSY MARKET OUTLOOK
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Type (Type 1, Type 2, Others)
10.2.2. By Diagnosis (Polysomnogram, Multiple Sleep Latency Test, Others)
10.2.3. By Treatment (Stimulants, Antidepressants, Sodium Oxybate, Others)
10.2.4. By End User (Hospitals, Clinics, Retail Pharmacies, Others)
10.2.5. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Narcolepsy Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Type
10.3.1.2.2. By Diagnosis
10.3.1.2.3. By Treatment
10.3.1.2.4. By End User
10.3.2. Argentina Narcolepsy Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Type
10.3.2.2.2. By Diagnosis
10.3.2.2.3. By Treatment
10.3.2.2.4. By End User
10.3.3. Colombia Narcolepsy Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Type
10.3.3.2.2. By Diagnosis
10.3.3.2.3. By Treatment
10.3.3.2.4. By End User
11. MIDDLE EAST AND AFRICA NARCOLEPSY MARKET OUTLOOK
11.1. Market Size & Forecast
11.1.1. By Value
11.2. Market Share & Forecast
11.2.1. By Type (Type 1, Type 2, Others)
11.2.2. By Diagnosis (Polysomnogram, Multiple Sleep Latency Test, Others)
11.2.3. By Treatment (Stimulants, Antidepressants, Sodium Oxybate, Others)
11.2.4. By End User (Hospitals, Clinics, Retail Pharmacies, Others)
11.2.5. By Country
11.3. MEA: Country Analysis
11.3.1. South Africa Narcolepsy Market Outlook
11.3.1.1. Market Size & Forecast
11.3.1.1.1. By Value
11.3.1.2. Market Share & Forecast
11.3.1.2.1. By Type
11.3.1.2.2. By Diagnosis
11.3.1.2.3. By Treatment
11.3.1.2.4. By End User
11.3.2. Saudi Arabia Narcolepsy Market Outlook
11.3.2.1. Market Size & Forecast
11.3.2.1.1. By Value
11.3.2.2. Market Share & Forecast
11.3.2.2.1. By Type
11.3.2.2.2. By Diagnosis
11.3.2.2.3. By Treatment
11.3.2.2.4. By End User
11.3.3. UAE Narcolepsy Market Outlook
11.3.3.1. Market Size & Forecast
11.3.3.1.1. By Value
11.3.3.2. Market Share & Forecast
11.3.3.2.1. By Type
11.3.3.2.2. By Diagnosis
11.3.3.2.3. By Treatment
11.3.3.2.4. By End User
12. MARKET DYNAMICS
12.1. Drivers
12.1.1 Increase in Prevalence of Narcolepsy
12.1.2 Growing Initiatives by Government Organizations
12.2. Challenges
12.2.1 Adverse effect related to narcolepsy drugs.
12.2.2 Misdiagnosis related to narcolepsy treatment
13. MARKET TRENDS & DEVELOPMENTS
13.1. Recent Development
13.2. Mergers & Acquisitions
13.3. Product Launches
14. GLOBAL NARCOLEPSY MARKET: SWOT ANALYSIS
15. PORTER’S FIVE FORCES ANALYSIS
15.1. Competition in the Industry
15.2. Potential of New Entrants
15.3. Power of Suppliers
15.4. Power of Customers
15.5. Threat of Substitute Products
16. COMPETITIVE LANDSCAPE
16.1. Business Overview
16.2. Product Offerings
16.3. Recent Developments
16.4. Financials (As Reported)
16.5. Key Personnel
16.6. SWOT Analysis
16.6.1 Jazz Pharmaceuticals Plc.
16.6.2 BIOPROJET.
16.6.3 Arena Pharmaceuticals, Inc.
16.6.4 Graymark Healthcare, Inc.
16.6.5 Mylan N.V.
16.6.6 Teva Pharmaceutical Industries Ltd.
16.6.7 Novartis AG.
16.6.8 Shire.
16.6.9 Shionogi Inc.
16.6.10 Ligand Pharmaceuticals, Inc.
17. STRATEGIC RECOMMENDATIONS
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. VOICE OF CUSTOMER
5. CLINICAL TRIAL ANALYSIS
5.1. Ongoing Clinical Trials
5.2. Completed Clinical Trials
5.3. Terminated Clinical Trials
5.4. Breakdown of Pipeline, By Development Phase
5.5. Breakdown of Pipeline, By Status
5.6. Breakdown of Pipeline, By Study Type
5.7. Breakdown of Pipeline, By Region
5.8. Clinical Trials Heat Map
6. GLOBAL NARCOLEPSY MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Type (Type 1, Type 2, Others)
6.2.2. By Diagnosis (Polysomnogram, Multiple Sleep Latency Test, Others)
6.2.3. By Treatment (Stimulants, Antidepressants, Sodium Oxybate, Others)
6.2.4. By End User (Hospitals, Clinics, Retail Pharmacies, Others)
6.2.5. By Company (2022)
6.3. Product Map
6.3.1 By Type
6.3.2 By Diagnosis
6.3.3 By Treatment
6.3.4 By End User
7. NORTH AMERICA NARCOLEPSY MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Type (Type 1, Type 2, Others)
7.2.2. By Diagnosis (Polysomnogram, Multiple Sleep Latency Test, Others)
7.2.3. By Treatment (Stimulants, Antidepressants, Sodium Oxybate, Others)
7.2.4. By End User (Hospitals, Clinics, Retail Pharmacies, Others)
7.2.5. By Country
7.3. North America: Country Analysis
7.3.1. United States Narcolepsy Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Type
7.3.1.2.2. By Diagnosis
7.3.1.2.3. By Treatment
7.3.1.2.4. By End User
7.3.2. Canada Narcolepsy Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Type
7.3.2.2.2. By Diagnosis
7.3.2.2.3. By Treatment
7.3.2.2.4. By End User
7.3.3. Mexico Narcolepsy Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Type
7.3.3.2.2. By Diagnosis
7.3.3.2.3. By Treatment
7.3.3.2.4. By End User
8. EUROPE NARCOLEPSY MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Type (Type 1, Type 2, Others)
8.2.2. By Diagnosis (Polysomnogram, Multiple Sleep Latency Test, Others)
8.2.3. By Treatment (Stimulants, Antidepressants, Sodium Oxybate, Others)
8.2.4. By End User (Hospitals, Clinics, Retail Pharmacies, Others)
8.2.5. By Country
8.3. Europe: Country Analysis
8.3.1. France Narcolepsy Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Type
8.3.1.2.2. By Diagnosis
8.3.1.2.3. By Treatment
8.3.1.2.4. By End User
8.3.2. Germany Narcolepsy Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Type
8.3.2.2.2. By Diagnosis
8.3.2.2.3. By Treatment
8.3.2.2.4. By End User
8.3.3. United Kingdom Narcolepsy Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Type
8.3.3.2.2. By Diagnosis
8.3.3.2.3. By Treatment
8.3.3.2.4. By End User
8.3.4. Italy Narcolepsy Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Type
8.3.4.2.2. By Diagnosis
8.3.4.2.3. By Treatment
8.3.4.2.4. By End User
8.3.5. Spain Narcolepsy Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Type
8.3.5.2.2. By Diagnosis
8.3.5.2.3. By Treatment
8.3.5.2.4. By End User
9. ASIA-PACIFIC NARCOLEPSY MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Type (Type 1, Type 2, Others)
9.2.2. By Diagnosis (Polysomnogram, Multiple Sleep Latency Test, Others)
9.2.3. By Treatment (Stimulants, Antidepressants, Sodium Oxybate, Others)
9.2.4. By End User (Hospitals, Clinics, Retail Pharmacies, Others)
9.2.5. By Country
9.3. Asia-Pacific: Country Analysis
9.3.1. China Narcolepsy Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Type
9.3.1.2.2. By Diagnosis
9.3.1.2.3. By Treatment
9.3.1.2.4. By End User
9.3.2. India Narcolepsy Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Type
9.3.2.2.2. By Diagnosis
9.3.2.2.3. By Treatment
9.3.2.2.4. By End User
9.3.3. Japan Narcolepsy Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Type
9.3.3.2.2. By Diagnosis
9.3.3.2.3. By Treatment
9.3.3.2.4. By End User
9.3.4. South Korea Narcolepsy Market Outlook
9.3.4.1. Market Size & Forecast
9.3.4.1.1. By Value
9.3.4.2. Market Share & Forecast
9.3.4.2.1. By Type
9.3.4.2.2. By Diagnosis
9.3.4.2.3. By Treatment
9.3.4.2.4. By End User
9.3.5. Australia Narcolepsy Market Outlook
9.3.5.1. Market Size & Forecast
9.3.5.1.1. By Value
9.3.5.2. Market Share & Forecast
9.3.5.2.1. By Type
9.3.5.2.2. By Diagnosis
9.3.5.2.3. By Treatment
9.3.5.2.4. By End User
10. SOUTH AMERICA NARCOLEPSY MARKET OUTLOOK
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Type (Type 1, Type 2, Others)
10.2.2. By Diagnosis (Polysomnogram, Multiple Sleep Latency Test, Others)
10.2.3. By Treatment (Stimulants, Antidepressants, Sodium Oxybate, Others)
10.2.4. By End User (Hospitals, Clinics, Retail Pharmacies, Others)
10.2.5. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Narcolepsy Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Type
10.3.1.2.2. By Diagnosis
10.3.1.2.3. By Treatment
10.3.1.2.4. By End User
10.3.2. Argentina Narcolepsy Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Type
10.3.2.2.2. By Diagnosis
10.3.2.2.3. By Treatment
10.3.2.2.4. By End User
10.3.3. Colombia Narcolepsy Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Type
10.3.3.2.2. By Diagnosis
10.3.3.2.3. By Treatment
10.3.3.2.4. By End User
11. MIDDLE EAST AND AFRICA NARCOLEPSY MARKET OUTLOOK
11.1. Market Size & Forecast
11.1.1. By Value
11.2. Market Share & Forecast
11.2.1. By Type (Type 1, Type 2, Others)
11.2.2. By Diagnosis (Polysomnogram, Multiple Sleep Latency Test, Others)
11.2.3. By Treatment (Stimulants, Antidepressants, Sodium Oxybate, Others)
11.2.4. By End User (Hospitals, Clinics, Retail Pharmacies, Others)
11.2.5. By Country
11.3. MEA: Country Analysis
11.3.1. South Africa Narcolepsy Market Outlook
11.3.1.1. Market Size & Forecast
11.3.1.1.1. By Value
11.3.1.2. Market Share & Forecast
11.3.1.2.1. By Type
11.3.1.2.2. By Diagnosis
11.3.1.2.3. By Treatment
11.3.1.2.4. By End User
11.3.2. Saudi Arabia Narcolepsy Market Outlook
11.3.2.1. Market Size & Forecast
11.3.2.1.1. By Value
11.3.2.2. Market Share & Forecast
11.3.2.2.1. By Type
11.3.2.2.2. By Diagnosis
11.3.2.2.3. By Treatment
11.3.2.2.4. By End User
11.3.3. UAE Narcolepsy Market Outlook
11.3.3.1. Market Size & Forecast
11.3.3.1.1. By Value
11.3.3.2. Market Share & Forecast
11.3.3.2.1. By Type
11.3.3.2.2. By Diagnosis
11.3.3.2.3. By Treatment
11.3.3.2.4. By End User
12. MARKET DYNAMICS
12.1. Drivers
12.1.1 Increase in Prevalence of Narcolepsy
12.1.2 Growing Initiatives by Government Organizations
12.2. Challenges
12.2.1 Adverse effect related to narcolepsy drugs.
12.2.2 Misdiagnosis related to narcolepsy treatment
13. MARKET TRENDS & DEVELOPMENTS
13.1. Recent Development
13.2. Mergers & Acquisitions
13.3. Product Launches
14. GLOBAL NARCOLEPSY MARKET: SWOT ANALYSIS
15. PORTER’S FIVE FORCES ANALYSIS
15.1. Competition in the Industry
15.2. Potential of New Entrants
15.3. Power of Suppliers
15.4. Power of Customers
15.5. Threat of Substitute Products
16. COMPETITIVE LANDSCAPE
16.1. Business Overview
16.2. Product Offerings
16.3. Recent Developments
16.4. Financials (As Reported)
16.5. Key Personnel
16.6. SWOT Analysis
16.6.1 Jazz Pharmaceuticals Plc.
16.6.2 BIOPROJET.
16.6.3 Arena Pharmaceuticals, Inc.
16.6.4 Graymark Healthcare, Inc.
16.6.5 Mylan N.V.
16.6.6 Teva Pharmaceutical Industries Ltd.
16.6.7 Novartis AG.
16.6.8 Shire.
16.6.9 Shionogi Inc.
16.6.10 Ligand Pharmaceuticals, Inc.
17. STRATEGIC RECOMMENDATIONS
